Table 2.
Univariate analysis of variables associated with MACE.
| Item | MACE (n = 42) | Event Free (n = 47) | p |
|---|---|---|---|
| Age, years | 61 ± 16 | 61 ± 15 | 0.96 |
| Sex, male, n (%) | 31 (74) | 33 (70) | 0.70 |
| CAD, n (%) | 14 (33) | 15 (32) | 0.89 |
| Diabetes, n (%) | 11 (26) | 13 (28) | 0.87 |
| Atrial fibrillation, n (%) | 11 (26) | 16 (34) | 0.42 |
| Care limitation, n (%) | 18 (43) | 21 (45) | 0.86 |
| Beta-blocker, n (%) | 27 (64) | 26 (55) | 0.74 |
| ACE inhibitor, n (%) | 24 (57) | 26 (55) | 0.86 |
| Aldosterone inhibitor, n (%) | 23 (55) | 23 (49) | 0.58 |
| CRT, n (%) | 13 (31) | 7 (15) | 0.08 |
| LVEF, % | 19 ± 6 | 20 ± 20 | 0.34 |
| Cardiac Index, L/min/m2 | 1.6 ± 0.5 | 1.8 ± 0.6 | 0.06 |
| TAPSE, mm | 12 ± 4 | 12 ± 4 | 0.94 |
| Admission | |||
| SBP, mmHg | 99 ± 14 | 109 ± 22 | 0.01 |
| DBP, mmHg | 60 ± 13 | 66 ± 13 | 0.04 |
| HR, bpm | 89 ± 18 | 93 ± 20 | 0.36 |
| Lactate, mM/L | 3.0 ± 2.6 | 3.2 ± 2.6 | 0.71 |
| Creatinine, μM/L | 169 ± 100 | 137 ± 62 | 0.10 |
| Nt-proBNP, pg/mL | 10,651 (5852–27,156) | 10,651 (5534–19,394) | 0.33 |
| ScVO2, % | 50 ± 7 | 49 ± 6 | 0.28 |
| Dobutamine, γ/kg/min | 6.7 ± 3.9 | 6.7 ± 3.9 | 0.98 |
| Furosemide, mg/h | 615 ± 387 | 800 ± 325 | 0.01 |
| At 72 h | |||
| SBP, mmHg | 101 ± 10 | 108 ± 19 | 0.04 |
| DBP, mmHg | 60 ± 10 | 63 ± 13 | 0.23 |
| HR, bpm | 93 ± 15 | 92 ± 25 | 0.89 |
| Diuresis, L per day | 3.4 ± 1.8 | 4.4 ± 1.9 | 0.02 |
| Dobutamine, γ/kg/min | 7.1 ± 3.9 | 6.2 ± 2.8 | 0.21 |
| Furosemide, mg/h | 582 ± 373 | 652 ± 382 | 0.38 |
| Norepinephrine, n (%) | 10 (24) | 3 (6) | 0.03 |
| Lactate, mmol/L | 2.0 ± 0.6 | 1.8 ± 0.6 | 0.38 |
| ScVO2, % | 50 ± 11 | 60 ± 10 | <0.001 |
| ScVO2 > 60% | 8 (19) | 22 (47) | 0.006 |
| At dobutamine weaning or at MACE | |||
| ScVO2, % | 53 ± 12 | 65 ± 6 | <0.001 |
| ScVO2 >60% | 13 (31) | 36 (77) | <0.001 |
Abbreviations: LV: left ventricular; CAD: coronary artery disease; dilated CM: dilated cardiomyopathy (idiopathic, toxic or post-myocarditis); Others: former valvular cardiopathy with functional prosthetic valve but persistent LV dysfunction; HF: heart failure; Care limitation indicates patients with a decision not to perform cardiac assistance or transplantation; ACE: Angiotensin Converting Enzyme; CRT: cardiac resynchronization therapy; LVEF: left ventricular ejection fraction; TAPSE: tricuspid annulus plane systolic excursion; SBP and DBP: systolic and diastolic blood pressure, respectively; HR: heart rate; eGFR: estimated glomerular filtration rate; NT-pro-BNP: N-Terminal pro Brain Natriuretic Peptid; H: hour; ScVO2: superior vena cava oxygen saturation; MACE: major adverse cardiovascular events.